Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 330 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative... June 30, 2025 Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... February 18, 2021 Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... August 25, 2020 Load more HOT NEWS What Do “Health Equity” and “Quality Care” Mean in Cancer Care? Holidays, Traditions and Grief Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with...
